Liposomal daunorubicin versus standard daunorubicin: Long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia

British Journal of Haematology

Volumn 143, Issue 5, 2008, Pages 681-689

  Latagliata, Roberto ^a   Breccia, Massimo ^a   Fazi, Paola ^b   Iacobelli, Simona ^b   Martinelli, Giovanni ^c   Di Raimondo, Francesco ^d   Sborgia, Marco ^e   Fabbiano, Francesco ^f   Pirrotta, Maria Teresa ^g   Zaccaria, Alfonso ^h   Amadori, Sergio ⁱ   Caramatti, Cecilia ^j   Falzetti, Franca ^k   Candoni, Anna ^l   Mattei, Daniele ^m   Morselli, Monica ⁿ   Alimena, Giuliana ^a   Vignetti, Marco ^b   Baccarani, Michele ^c   Mandelli, Franco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b GIMEMA Foundation   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e UO Ematologia Clinica   (Italy)

^f Divisione di Ematologia   (Italy)

^g Dipartimento di Medicina Clinica e Scienze Immunologiche   (Italy)

^h Dipartimento Oncologico   (Italy)

ⁱ S EUGENIO HOSPITAL   (Italy)

^j UNIVERSITY OF PARMA   (Italy)

^k UNIVERSITY OF PERUGIA   (Italy)

^l UNIVERSITY OF UDINE   (Italy)

^m AO Santa Croce e Carle   (Italy)

ⁿ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

more..

Author keywords

Acute myeloid leukaemia; DaunoXome; Elderly patients; Intensive chemotherapy

Indexed keywords

CYTARABINE; DAUNORUBICIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; THROMBOCYTE TRANSFUSION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIPOSOMES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 55949124199     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07400.x     Document Type: Article

References (24)

1. Amadori, S., Suciu, S., Jehn, U., Stasi, R., Thomas, X., Marie, J.P., Muus, P., Lefrere, F., Berneman, Z., Fillet, G., Denzlinger, G., Willemze, R., Leoni, P., Leone, G., Casini, M., Ricciuti, F., Vignetti, M., Beeldens, F., Mandelli, F. De Witte, T. for the EORTC/GIMEMA Leukemia Group (2005) Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukaemia: final results of AML-13, a randomized phase-3 study. Blood, 106, 27 34.
2. Anderson, J.E., Kopecky, K.J., Willman, C.L., Head, D., O'Donnell, M.W., Luthardt, F.W., Norwood, T.H., Chen, I.M., Balcerzak, S.P., Johnson, D.B. Appelbaum, F.R. (2002) Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood, 100, 3869 3876.
3. Bellott, R., Auvrignon, A., Leblamc, T., Pérel, Y., Gandemer, V., Bertrand, Y., Mechinaud, F., Bellenger, P., Vernois, J., Leverger, G., Baruchel, A. Robert, J. (2001) Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia. Cancer Chemotherapy Pharmacology, 47, 15 21.
4. Bieker, R., Lerchenmuller, C., Wehmeyer, J., Serve, H.L., Mesters, R.M., Buchner, T. Berdel, W.E. (2003) Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia. Oncology Report, 10, 915 920.
5. Buchner, T., Berdel, W.E., Schoch, C., Haferlach, T., Serve, H.L., Kienast, J., Schnittger, S., Kern, W., Tchinda, J., Reichle, A., Lengfelder, E., Staib, P., Ludwig, W.D., Aul, C., Eimermacher, H., Balleisen, L., Sauerland, M.C., Heinecke, A., Wormann, B. Hiddemann, W. (2006) Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukaemia. Journal of Clinical Oncology, 24, 2480 2489.
6. Clavio, M., Venturino, C., Pierri, I., Garrone, A., Miglino, M., Canepa, L., Balleari, E., Balocco, M., Michelis, G.L., Ballerini, F. Gobbi, M. (2004) Combination of liposomal daunorubicin (DaunoXome), fludarabine and cytarabine (FLAD) in patients with poor-risk acute leucemia. Annals of Hematology, 83, 696 703.
7. Cortes, J., O'Brian, S., Estey, E., Giles, F., Keating, M. Kantarjian, H. (1999) Phase I study of liposomal daunorubicin in patients with acute leukaemia. Investigational New Drugs, 17, 81 87.
8. Cortes, J., Estey, E., O'Brien, S., Giles, F., Shen, Y., Koller, C., Beran, M., Thomas, D., Keating, M. Kantarjian, K. (2001) High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leucemia. Cancer, 92, 7 14.
9. Ewer, M.S., Martin, F.J., Henderson, C., Shapiro, C.L., Benjamin, R.S. Gabizon, A.A. (2004) Cardiac safety of liposomal anthracyclines. Seminars in Oncology, 31, 161 181.
10. Fassas, A. Anagnostopoulos, A. (2005) The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukaemia. Leukemia and Lymphoma, 46, 795 802.
11. Fassas, A., Buffels, R., Anagnostopoulos, A., Gacos, E., Vadikolia, C., Haloudis, P. Kaloyannidis, P. (2002) Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study. British Journal of Haematology, 116, 308 315.
12. Frohling, S., Schlenk, R.F., Kayser, S., Morhardt, M., Benner, A., Dohner, K. Dohner, H. for German-Austrian AML Study Group (2006) Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukaemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood, 108, 3280 3288.
13. Godwin, J.E., Kopecky, K.J., Head, D.R., Willman, C.L., Leith, C.P., Hynes, H.E., Balcerzak, S.P. Appelbaum, F.R. (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukaemia: a Southwest oncology group study. Blood, 91, 3607 3615.
14. Jehn, U., Suciu, S., Thomas, X., Lefrere, F., Muus, P., Berneman, Z., Marie, J.P., Adamo, F., Fillet, G., Nobile, F., Ricciuti, F., Leone, G., Rizzoli, V., Montanaro, M., Beeldens, F., Fazi, P., Mandelli, F., Willemze, R., De Witte, T. Amadori, S. (2006) Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukaemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial. Leukemia, 20, 1723 1730.
15. Krishna, R. Mayer, L.D. (1997) Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumor. Cancer Research, 57, 5246 5253.
16. Leith, C.P., Kopecky, K.J., Godwin, J., McConnell, T., Slovak, M.L., Chen, I.M., Head, D.R., Appelbaum, F.R. Willman, C.L. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89, 3323 3329.
17. Liu, F.T., Kelsey, S.M., Newland, A.C. Jia, L. (2002) Liposomal encapsulation diminishes daunorubicin-induced generation of reactive oxygen species, depletion of ATP and necrotic cell death in human leukaemic cells. British Journal of Haematology, 117, 333 342.
18. Lowenberg, B., Suciu, S., Archimbaud, E., Haak, H., Stryckmans, P., de Cataldo, R., Dekker, A.W., Berneman, T.N., Thyss, A., van der Lelie, J., Sonneveld, P., Visani, G., Fillet, G., Hayat, M., Hagemejier, A., Solbu, G. Zittoun, R. (1998) Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy. The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the LCG of the EORTC and the Dutch-Belgian Hemato-Oncology Coopeative Hovon Group randomized phase III study AML-9. Journal of Clinical Oncology, 16, 872 881.
19. Pea, F., Russo, D., Michieli, M., Baraldo, M., Ermacora, A., Damiani, D., Baccarani, M. Furlanut, M. (2000) Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia. Cancer Chemotherapy Pharmacology, 46, 279 286.
20. Rowe, J.M., Neuberg, D., Friedenberg, W., Bennett, J.M., Paietta, E., Makary, A.Z., Liesveld, J.L., Abbound, C.N., Dewald, J., Hayes, F.A., Tallman, M.S. Wiernik, P.H. (2004) A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood, 103, 479 485.
21. Russo, D., Piccaluga, P.P., Michieli, M., Michelutti, T., Visani, G., Gugliotta, L., Bonini, A., Pierri, I., Gobbi, M., Tiribelli, M., Fanin, R., Piccolrovazzi, S. Baccarani, M. (2002) Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leulkemia. Annals of Hematology, 81, 462 466.
22. Schaich, M., Illmer, T., Aulitzky, W., Bodenstein, H., Clemens, M., Neubauer, A., Repp, R., Schakel, U., Soucek, S., Wandt, H. Ehninger, G. (2002) Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-c for elderly acute myeloid leukemia patients aged 61-65 years. Haematologica, 87, 808 815.
23. Schlenk, R.F., Frohling, S., Hartmann, F., Fischer, J.T., Glasmacker, A., Del Valle, F., Gotze, K., Nerl, C., Schoch, R., Pralle, H., Mergenthaler, H.G., Hensel, M., Koller, E., Kirchen, H., Matzdorff, A., Salwender, H., Biedermann, H.G., Kremers, S., Haase, D., Benner, A., Dohner, K. Dohner, H. (2006) Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukaemia in first remission: results of second randomization of the AML HD98-B treatment trial. Leukemia, 20, 748 750.
24. Theodoulou, M. Hudis, C. (2004) Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer, 100, 2052 2063.